Mazdutide

Key Points

• Mazdutide has been approved in China but is yet to gain approval in the UK - estimated approval - 2026/2027
• Side effects are predominantly GI related (nausea, vomiting, diarrhoea)
• Mazdutide is a dual treatment: GLP-1 and GCGR
• Up to 21% weight loss in trial participants
• Improvements seen in blood sugar, liver fat content and waist circumference

How does Mazdutide work?

Mazdutide is a dual agonist peptide : a glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCGR).This means it works on two hormone pathways in the body, designed to produce a greater weight loss than a GLP-1 alone.

GLP-1: Helps to keep you full, quicker, for longer.
GCGR: Has been shown to reduce body weight and blood glucose levels.

Mazdutide has been trialled in patients with diabetes and has been shown to reduce HbA1c. As well as this, a study observed that 9mg of Mazdutide significantly reduced liver fat content and also a significant reduction in waist circumference.

How effective is Mazdutide?

In early phase trials, doses up to 16mg were administered in adults with overweight or obesity. After 20 weeks, there was a significant amount of weight loss achieved by those in the medication group in comparison to those who administered a placebo.

Cohort	Mean weight loss	Individuals who achieved mean weight loss	Mean change in waist circumference
1 (n=12)	20%	66.7%	12%
2 (n=12)	21%	75%	17%
3 (n=8)	0.1%	-	0.8%

In another trial, consisting of 610 participants, the results demonstrated a clear superior.

Group	Mean change in body weight from baseline - Week 32	Weight reduction of at least 5%	Mean change in body weight from baseline - Week 48	Weight reduction of at least 15%
4mg	10.09%	73.9%	11%	35.7%
6mg	12.55%	82%	14.01%	49.5%
Placebo	0.45%	10.5%	0.3%	2.0%

What are the side effects of Mazdutide?

Mazdutide has a similar side effect profile to some of the weight loss medications you may already be familiar with.

Gastrointestinal side effects are the most common. These include:

• Nausea
• Vomiting
• Diarrhoea
• Bloating or abdominal discomfort

Upper respiratory tract infections were also reported in some participants. However, this was seen across all participant groups, including the placebo group.

Who would not be suitable for Mazdutide

Mazdutide is currently under development and new information regarding this treatment, including who it will be suitable for, has not yet been confirmed. Based on what we know about GLP-1s, Mazdutide will not be suitable for:

• Pregnant or breastfeeding women
• Those who have plans to become pregnant in the near future
• Individuals who have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2)
• A history of pancreatitis
• Active gallstones or issues with your gallbladder

FAQs